By proceeding, you agree to our Terms of Use and Privacy Policy.
Hong Jiang, Senior Scientist, Analytical Development, Biogen With the commercial success of Antisense oligonucleotides (ASO) drugs, the footprint of this class of new and exciting therapeutics is quickly increasing in the clinical space. It is vitall
Talks About #Science
Preferred Locations #NorthAmerica
OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process.
